Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of obeticholic acid + bezafibrate fixed-dose combination in primary biliary cholangitis
NL-OMON60170Phase 3Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of obeticholic acid and bezafibrate in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Primary endpoints: ALP response and normalization, Normalization of liver biochemistry and 3 more. Started Apr 2025; status: completed.
02
Drugs
obeticholic acidbezafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON60170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60170.